Source comparison
Thymosin Alpha-1 vs Other Research Peptides: Clinical Comparison
Thymosin Alpha-1 Thymic T-cell maturation, TLR activation, cytokine upregulation (IL-2, IFN-gamma) Toll-like receptors (TLR-9), dendritic cell surface markers 1.6–3.2mg SC twice weekly ~2 hours Immune modulation, viral clearance studies, T-cell function optimi
This comparison does not assign a generated winner or score.
- Thymosin Alpha-1
- Thymic T-cell maturation, TLR activation, cytokine upregulation (IL-2, IFN-gamma)
- Toll-like receptors (TLR-9), dendritic cell surface markers
- 1.6–3.2mg SC twice weekly
- ~2 hours
- Immune modulation, viral clearance studies, T-cell function optimization
- Immune-specific; zero metabolic or anabolic overlap with GH or GLP-1 pathways
- GHRP-2
- Ghrelin receptor agonism, pulsatile GH secretion
- GHS-R1a (growth hormone secretagogue receptor)
- 100–300mcg SC 1–3x daily
- 30–45 minutes (GH pulse lasts 2–4 hours)
- Growth hormone release studies, body composition research
- Pure GH secretagogue; no immune or incretin activity
- Semaglutide
- GLP-1 receptor agonism, gastric emptying delay, insulin potentiation
- GLP-1 receptors (pancreatic beta cells, CNS, GI tract)
- 0.25–2.4mg SC weekly
- 7 days
- Metabolic health, weight loss, glycemic control studies
- Metabolic and satiety-focused; no immune or GH modulation
- BPC-157
- Angiogenesis promotion, VEGF upregulation, nitric oxide pathway modulation
- Growth factor receptors, endothelial cells
- 200–500mcg SC daily
- Data limited; estimated 4–6 hours
- Tissue repair, injury recovery, GI healing research
- Repair-specific; no direct immune, GH, or metabolic receptor activity
- TB-500 (Thymosin Beta-4 fragment)
- Actin sequestration, cell migration, anti-inflammatory cytokine modulation
- Intracellular actin binding (non-receptor-mediated)
- 2–5mg SC twice weekly
- ~24 hours
- Wound healing, inflammation reduction, tissue regeneration
- Structural repair peptide; distinct from Tα1 despite naming similarity